DXCM vs NAUT · P/E 63, rev $2.50B vs $103.4M cap
DexCom Inc (DXCM) versus Nautilus Biotechnology Inc (NAUT) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Nautilus Biotechnology Inc (NAUT) is a biotechnology company listed on US.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
NAUT does not have a complete income-statement cache yet.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. NAUT currently screens at market cap $103.4M.
Not investment advice. Open the DXCM and NAUT stock pages for the full models.
Not investment advice.